Literature DB >> 16402923

Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance.

Shinya Makino1, Hiroshi Handa, Koji Suzukawa, Masayoshi Fujiwara, Masaharu Nakamura, Shogo Muraoka, Ikumi Takasago, Yasushi Tanaka, Kozo Hashimoto, Tamotsu Sugimoto.   

Abstract

OBJECTIVE: To investigate whether sleep-disordered breathing and/or plasma adiponectin levels are associated with insulin resistance independent of obesity or fat distribution in obstructive sleep apnoea syndrome (OSAS).
DESIGN: Cross-sectional clinical study. PATIENTS: Two-hundred and thirteen Japanese patients with OSAS aged 27-80 years were divided into three groups: 30 with mild OSAS [apnoea-hypopnoea index (AHI) = 10.3 +/- 0.9 episodes/h, minimum oxygen saturation (min SpO2) = 87.3 +/- 0.9%], 98 with moderate OSAS (AHI = 28.9 +/- 0.6 episodes/h, min SpO2 = 82.1 +/- 0.7%), and 85 with severe OSAS (AHI = 68.1 +/- 2.8 episodes/h, min SpO2 = 72.3 +/- 1.6%). Twenty-one patients undergoing diabetic treatments (two mild, nine moderate and 10 severe) were excluded from the assessment of insulin resistance and plasma adiponectin measurements. MEASUREMENTS: Fat distribution [evaluated according to visceral (V) and subcutaneous (S) fat areas using computed tomography scanning at the umbilical level], blood pressure, metabolic parameters and hormones including insulin and adiponectin were measured. After full polysomnography, venous blood was collected between 0600 and 0700 h.
RESULTS: Severe OSAS patients were more hypertensive than mild and moderate OSAS. Fasting plasma glucose (FPG) and fasting plasma insulin and homeostasis model assessment of insulin resistance (HOMA-IR) levels were all higher in severe OSAS than mild and moderate OSAS patients. HOMA-IR was correlated not only with obesity [body mass index (BMI), V and S areas] but also with apnoea (AHI, min SpO2 and desaturation time). Additionally, HOMA-IR was correlated positively with haemoglobin (Hb)A1c, systolic (SBP) and diastolic blood pressure (DBP), triglycerides and free fatty acids (FFA), and negatively with high density lipoprotein (HDL)-cholesterol, suggesting that insulin resistance is a key component of the metabolic syndrome in OSAS. Plasma adiponectin levels were not different between mild, moderate and severe OSAS groups. Plasma adiponectin levels were correlated with HOMA-IR and V area, but not AHI or min SpO2. Stepwise multiple regression analysis, however, revealed that BMI, AHI and plasma adiponectin were independently associated with HOMA-IR.
CONCLUSION: Sleep-disordered breathing was associated with insulin resistance independent of obesity. Although plasma adiponectin was also an independent determinant of HOMA-IR in OSAS patients, plasma adiponectin was more closely related to obesity than to sleep apnoea. Although treatment of sleep-disordered breathing with nasal continuous positive airway pressure reportedly improves insulin sensitivity, our findings suggest that treatment of obesity is also essential in ameliorating insulin resistance at least through increased plasma adiponectin levels in OSAS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16402923     DOI: 10.1111/j.1365-2265.2005.02407.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  49 in total

Review 1.  Biomarkers associated with obstructive sleep apnea: A scoping review.

Authors:  Graziela De Luca Canto; Camila Pachêco-Pereira; Secil Aydinoz; Paul W Major; Carlos Flores-Mir; David Gozal
Journal:  Sleep Med Rev       Date:  2014-11-28       Impact factor: 11.609

2.  Sleep Apnea and Metabolic Dysfunction: Cause or Co-Relation?

Authors:  R Nisha Aurora; Naresh M Punjabi
Journal:  Sleep Med Clin       Date:  2007-06-01

3.  Effects of sleep apnea on nocturnal free fatty acids in subjects with heart failure.

Authors:  Jonathan C Jun; Luciano F Drager; Samer S Najjar; Stephen S Gottlieb; Cynthia D Brown; Philip L Smith; Alan R Schwartz; Vsevolod Y Polotsky
Journal:  Sleep       Date:  2011-09-01       Impact factor: 5.849

4.  Neuroendocrine alterations in obese patients with sleep apnea syndrome.

Authors:  Fabio Lanfranco; Giovanna Motta; Marco Alessandro Minetto; Matteo Baldi; Marcella Balbo; Ezio Ghigo; Emanuela Arvat; Mauro Maccario
Journal:  Int J Endocrinol       Date:  2010-02-23       Impact factor: 3.257

5.  Serum omentin levels in patients with obstructive sleep apnea.

Authors:  Ozlem Kar Kurt; Mehmet Tosun; Aytekin Alcelik; Beyhan Yilmaz; Fahrettin Talay
Journal:  Sleep Breath       Date:  2013-10-03       Impact factor: 2.816

Review 6.  Sleep Duration and Diabetes Risk: Population Trends and Potential Mechanisms.

Authors:  Michael A Grandner; Azizi Seixas; Safal Shetty; Sundeep Shenoy
Journal:  Curr Diab Rep       Date:  2016-11       Impact factor: 4.810

Review 7.  Sleep-disordered breathing and obesity: pathophysiology, complications, and treatment.

Authors:  Corey J Leinum; John M Dopp; Barbara J Morgan
Journal:  Nutr Clin Pract       Date:  2009-12       Impact factor: 3.080

8.  Ghrelin, leptin, adiponectin, and resistin levels in sleep apnea syndrome: Role of obesity.

Authors:  Ahmet Ursavas; Yesim Ozarda Ilcol; Nazan Nalci; Mehmet Karadag; Ercument Ege
Journal:  Ann Thorac Med       Date:  2010-07       Impact factor: 2.219

9.  Sleep and metabolism: an overview.

Authors:  Sunil Sharma; Mani Kavuru
Journal:  Int J Endocrinol       Date:  2010-08-02       Impact factor: 3.257

10.  HbA1c is associated with severity of obstructive sleep apnea hypopnea syndrome in nondiabetic men.

Authors:  Nikolaos Papanas; Paschalis Steiropoulos; Evangelia Nena; Argyris Tzouvelekis; Efstratios Maltezos; Georgia Trakada; Demosthenes Bouros
Journal:  Vasc Health Risk Manag       Date:  2009-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.